<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04886284</url>
  </required_header>
  <id_info>
    <org_study_id>2021-7400</org_study_id>
    <nct_id>NCT04886284</nct_id>
  </id_info>
  <brief_title>Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia</brief_title>
  <acronym>CERT</acronym>
  <official_title>Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia (CERT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Todd C. Lee MD MPH FIDSA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>McGill University Health Centre/Research Institute of the McGill University Health Centre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is a variety of in vitro, in vivo (animal model), and human case series data which&#xD;
      suggests that the addition of ertapenem to cefazolin could improve outcomes in&#xD;
      methicillin-susceptible S. aureus bacteremia. No randomized controlled trial has been&#xD;
      performed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cefazolin is licensed in Canada for the management of infections due to susceptible&#xD;
      Staphylococcus aureus, including bacteremia. It has been commonly used for decades in this&#xD;
      disease and, when compared in observational studies to anti-staphylococcal penicillins, has&#xD;
      demonstrated reduced mortality.&#xD;
&#xD;
      Nevertheless, in the treatment of methicillin-susceptible S. aureus (MSSA) bacteremia, there&#xD;
      remains significant opportunities to improve clinical outcomes. Indeed, S. aureus bacteremia&#xD;
      kills more Canadians annually than myeloma, melanoma, renal, ovarian or stomach cancers.&#xD;
      Overall mortality approached 18% in a recent Canadian clinical trial performed by our group&#xD;
      (Cheng et al, 2020).&#xD;
&#xD;
      The duration of bacteremia, particularly after antibiotherapy is recognized as a major risk&#xD;
      factor for mortality. Interventions which reduce the duration of bacteremia, without&#xD;
      increasing the frequency of renal failure like gentamicin (Cosgrove et al, 2009) or the&#xD;
      combination of vancomycin and flucloxacillin in MRSA (Tong et al, 2020), are among the most&#xD;
      promising candidates for larger phase 3 studies designed to impact patient mortality.&#xD;
&#xD;
      Ertapenem is a commonly used antibiotic which has been on the Canadian market for more than&#xD;
      15 years. It is most commonly used in patients with infections caused by extended-spectrum&#xD;
      beta-lactamase producing Enterobacteraciae; however, it has a broad spectrum of activity&#xD;
      including Gram-positive bacteria such as S. aureus. Indeed, the drug is licensed in Canada&#xD;
      for the treatment of complicated skin and soft tissue infections commonly caused by S.&#xD;
      aureus.&#xD;
&#xD;
      In S. aureus the carbapenem antibiotics like ertapenem have exceptional affinity to the&#xD;
      essential penicillin-binding protein (PBP), PBP1, exceeding even that of the&#xD;
      antistaphylococcal β-lactams (Chambers et al, 1990). This complements the relative PBP2&#xD;
      proclivity of cefazolin (Bamberger et al, 2002).&#xD;
&#xD;
      The combination of cefazolin with ertapenem has also been shown to be synergistic in vitro&#xD;
      (Sakoulas et al, 2016), in vivo in the mouse and rat models (Sakoulas et al, 2016; Ulloa et&#xD;
      al, 2020), and in a small human case series (Ulloa et al, 2020).&#xD;
&#xD;
      Based on this data, there is compelling theory (attack on 2 PBPs), in vitro, in vivo, and&#xD;
      human case evidence to support an exploratory phase 2 RCT of cefazolin-ertapenem for the&#xD;
      treatment of MSSA bacteremia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical success</measure>
    <time_frame>Day 5</time_frame>
    <description>Composite of: Patient alive, fever resolved, blood cultures negative for S. aureus, systolic blood pressure &gt;=90mmHg not on vasopressors</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood culture clearance</measure>
    <time_frame>30 days</time_frame>
    <description>Time between first positive and first negative blood culture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical improvement</measure>
    <time_frame>30 days</time_frame>
    <description>Time to clinical improvement defined as the time until fever resolved, blood cultures sterile, and systolic blood pressure &gt;=90mmHg not on vasopressors in patients who survive to clinical improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay</measure>
    <time_frame>90 days</time_frame>
    <description>The time from initial emergency room visit until discharge from hospital in patients discharged alive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause-mortality</measure>
    <time_frame>90 days</time_frame>
    <description>Death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Valve replacement surgery</measure>
    <time_frame>56 days</time_frame>
    <description>Any valve replacement surgery occurring after the initial diagnosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent isolation of MSSA from a sterile site</measure>
    <time_frame>Between Days 6 and 90 inclusive</time_frame>
    <description>Any positive culture of MSSA from a sterile site (blood, cerebral spinal fluid, joint aspirate, bone, etc.) occurring after the end of combination therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seizure</measure>
    <time_frame>7 days</time_frame>
    <description>Any clinically identified seizure within 48 hours of discontinuation of combination therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Kidney Injury</measure>
    <time_frame>7 days</time_frame>
    <description>An increase in serum creatinine to ≥1.5 times baseline OR new requirement for hemodialysis at any time in the first 7 days from randomization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Staphylococcus Aureus Bacteremia</condition>
  <condition>Staphylococcus Aureus Septicemia</condition>
  <condition>Staphylococcal Sepsis</condition>
  <condition>Staphylococcus Aureus Endocarditis</condition>
  <arm_group>
    <arm_group_label>Ertapenem</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ertapenem 1g IV daily infused over 2 hours x 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline placebo infused daily over 2 hours x 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ertapenem</intervention_name>
    <description>Adjunctive ertapenem</description>
    <arm_group_label>Ertapenem</arm_group_label>
    <other_name>Invanz</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult &gt;=18 years old&#xD;
&#xD;
          2. S. aureus bacteremia within the past 48 hours:&#xD;
&#xD;
               -  with any unknown MRSA status (in centers with &lt;15% prevalence of MRSA in their&#xD;
                  annual blood cultures) or known negative MRSA screening swab within 90 days OR&#xD;
&#xD;
               -  which has already been shown to be MSSA&#xD;
&#xD;
          3. Current receipt of cefazolin or where it would be clinically appropriate (according to&#xD;
             treating ID specialist) to switch to cefazolin as the backbone therapy (open label,&#xD;
             non-study drug).&#xD;
&#xD;
        NOTE: Up to an additional 12-24 hours of open label non-study VANCOMYCIN, LINEZOLID or&#xD;
        DAPTOMYCIN may be allowed if there is sepsis and clinical concern for MRSA has not been&#xD;
        excluded.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Clinical:&#xD;
&#xD;
          1. At time of recruitment, the patient has already clinically improved with at least one&#xD;
             subsequent negative culture at &gt;24 hours incubation&#xD;
&#xD;
          2. Anaphylaxis to any beta-lactam antibiotic (and any allergy to ertapenem) Polymicrobial&#xD;
             bacteremia (not including skin commensals)&#xD;
&#xD;
          3. Known seizure disorder&#xD;
&#xD;
          4. Any receipt of valproic acid&#xD;
&#xD;
          5. Expected mortality within 48 hours&#xD;
&#xD;
          6. Need for critical care resources but &quot;do not resuscitate&quot; status precludes the receipt&#xD;
             of critical care&#xD;
&#xD;
          7. Unable to provide informed consent and no available healthcare proxy (with ethics&#xD;
             approval for deferred consent in cases of severe illness)&#xD;
&#xD;
        Administrative:&#xD;
&#xD;
          1. Refusal to provide informed consent&#xD;
&#xD;
          2. Refusal of healthcare team to participate&#xD;
&#xD;
          3. No reliable means of outpatient contact (telephone/email/text)&#xD;
&#xD;
          4. Previously enrolled&#xD;
&#xD;
          5. Patients whose isolate is identified as MRSA post-enrollment will be subsequently&#xD;
             excluded (see below).&#xD;
&#xD;
        Note that because MSSA is much more common than MRSA in Canada (90% of all S. aureus&#xD;
        bacteremia at MUHC, for example, are MSSA and in the presence of a negative MRSA screening&#xD;
        swab or unknown MRSA status, this means that the risk of MRSA is less than 5%). We believe&#xD;
        time to combination therapy is likely linked to benefit, therefore we will recruit the&#xD;
        patients as soon as S. aureus is identified but potentially prior to confirmation the&#xD;
        organism is MSSA. Where possible, rapid MRSA detection techniques will be deployed; however&#xD;
        with conventional screening this will mean approximately a 12-24 hours delay. Organisms&#xD;
        subsequently identified as MRSA will be excluded from the intention to treat analysis and&#xD;
        the sample size will be adjusted accordingly to ensure the total enrollment meets study&#xD;
        goals.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Todd C Lee, MD MPH FIDSA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Institute of the McGill University Health Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emily G McDonald, MD MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Institute of the McGill University Health Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Matthew P Cheng, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Institute of the McGill University Health Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sarah Elsayed</last_name>
    <phone>514-934-1934</phone>
    <phone_ext>23730</phone_ext>
    <email>sarah.elsayed@idtrials.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>McGill University Health Centre (Royal Victoria Hospital and Montreal General Hospital)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Ulloa ER, Singh KV, Geriak M, Haddad F, Murray BE, Nizet V, Sakoulas G. Cefazolin and Ertapenem Salvage Therapy Rapidly Clears Persistent Methicillin-Susceptible Staphylococcus aureus Bacteremia. Clin Infect Dis. 2020 Sep 12;71(6):1413-1418. doi: 10.1093/cid/ciz995.</citation>
    <PMID>31773134</PMID>
  </reference>
  <reference>
    <citation>Sakoulas G, Olson J, Yim J, Singh NB, Kumaraswamy M, Quach DT, Rybak MJ, Pogliano J, Nizet V. Cefazolin and Ertapenem, a Synergistic Combination Used To Clear Persistent Staphylococcus aureus Bacteremia. Antimicrob Agents Chemother. 2016 Oct 21;60(11):6609-6618. doi: 10.1128/AAC.01192-16. Print 2016 Nov.</citation>
    <PMID>27572414</PMID>
  </reference>
  <reference>
    <citation>Cosgrove SE, Vigliani GA, Fowler VG Jr, Abrutyn E, Corey GR, Levine DP, Rupp ME, Chambers HF, Karchmer AW, Boucher HW. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin Infect Dis. 2009 Mar 15;48(6):713-21. doi: 10.1086/597031.</citation>
    <PMID>19207079</PMID>
  </reference>
  <reference>
    <citation>Bamberger DM, Herndon BL, Fitch J, Florkowski A, Parkhurst V. Effects of neutrophils on cefazolin activity and penicillin-binding proteins in Staphylococcus aureus abscesses. Antimicrob Agents Chemother. 2002 Sep;46(9):2878-84.</citation>
    <PMID>12183241</PMID>
  </reference>
  <reference>
    <citation>Chambers HF, Sachdeva M. Binding of beta-lactam antibiotics to penicillin-binding proteins in methicillin-resistant Staphylococcus aureus. J Infect Dis. 1990 Jun;161(6):1170-6.</citation>
    <PMID>2345297</PMID>
  </reference>
  <reference>
    <citation>Cheng MP, Lawandi A, Butler-Laporte G, De l'Étoile-Morel S, Paquette K, Lee TC. Adjunctive Daptomycin in the Treatment of Methicillin-susceptible Staphylococcus aureus Bacteremia: A Randomized, Controlled Trial. Clin Infect Dis. 2021 May 4;72(9):e196-e203. doi: 10.1093/cid/ciaa1000.</citation>
    <PMID>32667982</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 10, 2021</study_first_submitted>
  <study_first_submitted_qc>May 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2021</study_first_posted>
  <last_update_submitted>May 10, 2021</last_update_submitted>
  <last_update_submitted_qc>May 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>McGill University Health Centre/Research Institute of the McGill University Health Centre</investigator_affiliation>
    <investigator_full_name>Todd C. Lee MD MPH FIDSA</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Staphylococcus aureus</keyword>
  <keyword>Methicillin-susceptible</keyword>
  <keyword>Bacteremia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Staphylococcal Infections</mesh_term>
    <mesh_term>Bacteremia</mesh_term>
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Endocarditis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ertapenem</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

